Özet:

In our study, some benzimidazole-thiadiazole derivative compounds were designed to develop new anticancer drugs, and their structures were proven by 1H-NMR, 13C-NMR, and elemental analysis spectral data. The cytotoxic activities of the compounds were evaluated by comparing the reference compound fluorouracil using the MTT method on the HT29 cell line. In addition, the cytotoxic effect of the compounds against the L929 (healthy mouse fibroblast cell) cell line was evaluated in order to determine the selectivity of the compounds. When the IC50 values of the compounds are examined, the structure of 5-(2-(2,6-dimethoxyphenyl)-1H-benz[d]imidazol-5(6)-yl)-N-cyclohexyl-1,3,4-thiadiazol-2-amine (BT-2) compound with an IC50 value of 34.13±2.48 µM showed comparable efficacy to the reference drug fluorouracil (12.84 ± 3.66 µM). It was determined that the cytotoxic effect of BT-2 compound on L929 healthy cell line was lower than the reference drug. These results are promising in terms of improving the anticancer effect of BT-2 compound. In addition, TAS and TOS of the compounds and antioxidant properties of the compounds were evaluated. The TOS value of the BT-2 compound appears to be comparable to the control drug.